Abstract
Mild cognitive impairment (MCI) and dementia present critical health challenges in aging populations, highlighting the need for prompt and accurate diagnostic methods. Current diagnostic approaches for dementia are constrained by limited access to specialists and the high cost or invasiveness of the diagnostic methods, necessitating the development of widely accessible, cost-effective, and noninvasive alternatives. Electroencephalography (EEG) is a promising, accessible, cost-effective, noninvasive biomarker of dementia. However, traditional EEG systems are limited by their lack of portability and need for skilled technicians. This study proposes a deep-learning-based model to differentiate healthy volunteers (HVs) from patients with dementia-related conditions using data from portable EEG devices. A dataset of 233 participants, including 119 HVs and 114 patients categorized by severity and clinical diagnosis, was analyzed. We developed a customized transformer-based model to analyze the EEG data transformed into frequency-domain features using a short-time Fourier transform. The model was evaluated using 10-fold cross-validation and a hold-out dataset. In cross-validation, the model achieved an area under the curve (AUC) of 0.872 and a balanced accuracy (bACC) of 80.8% in distinguishing HVs from patients. Subgroup analyses by severity and clinical diagnosis yielded AUCs of 0.812 to 0.898 and bACCs of 74.9 to 86.4%, respectively. Comparable performance was observed in the holdout dataset, except for small sample sizes. These findings highlight the potential of portable EEG devices and deep-learning models as practical tools for dementia screening.
Competing Interest Statement
BN, SY, and KE are employed by PGV Inc. MH and TY work as technical advisors to PGV Inc. The authors acknowledge PGV Inc. for providing general support during this study.
Clinical Trial
UMIN 000042903
Funding Statement
This study was financially supported by PGV Inc., Tokyo, Japan.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was performed according to the principles of the Declaration of Helsinki, approved by the Ethics Review Committee of Osaka University Hospital, and registered in the UMIN Clinical Trial Registry (UMIN 000042903).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Availability of data and materials
All data generated or analyzed in this study are available from the corresponding author upon reasonable request, following additional ethical approval regarding data provision to individual institutions.
